USA 12d left
Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression — In Vivo Validation
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.FOOD AND DRUG ADMINISTRATION.FDA OFFICE OF ACQ GRANT SVCS
Posted: Aug 26, 2026
Due Date
Sep 10, 2026
